Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Clinical Efficacy Assessment of Digitally Fabricated PEEK Barrier Membranes for Guided Bone Regeneration in Severe Bone Defects

31 oktober 2026 uppdaterad av: Fuming He
  1. Research background: Guided bone regeneration (GBR), as a bone augmentation technique, is widely used for the reconstruction of hard-tissue defects in implant dentistry. Terheyden classified bone defects into four types according to the spatial relationship between the defect and the intended implant site. Among these, type 2/4, 3/4, and 4/4 are recommended to be managed with a staged protocol: bone augmentation first, followed by dental implant placement. The selection of barrier membranes for GBR depends on the size of the bone defect, and severe three-dimensional bone deficiencies require additional mechanical support. The digitally fabricated PEEK biological barrier is a product of the world's first digital PEEK bone augmentation system newly developed by Kangtuo Medical Group in 2026. It enables predictable bone gain and contour reconstruction, adapts to irregularly shaped bone defects, and provides complete cell exclusion as well as full soft-tissue isolation without the need for an overlying membrane. The system supports full-workflow planning and clinician-driven design. Being radiolucent, it facilitates sequential observation of bone remodeling, and the device is also easy to retrieve. Nevertheless, its clinical performance following GBR in severe bone defect sites remains to be further evaluated.
  2. Research objective: To evaluate the bone stability and soft tissue healing outcomes following guided bone regeneration (GBR) using a digital PEEK biological barrier in sites with severe bone defects. This study aims to provide evidence based references for clinicians when selecting barrier membranes, so as to facilitate optimal clinical decision making for bone augmentation.
  3. Study design and methods: Design type: multicentral prospective clinical study. Study duration: 3 years. Start time: From the date of adoption of ethics. End time: 2029. For all included patients, cone beam computed tomography (CBCT) scans and intraoral scans will be performed preoperatively, immediately postoperatively, and at 6-8 months postoperatively.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Intervention / Behandling

Detaljerad beskrivning

  1. Research background: Guided bone regeneration (GBR), as a bone augmentation technique, is widely used for the reconstruction of hard-tissue defects in implant dentistry. Terheyden classified bone defects into four types according to the spatial relationship between the defect and the intended implant site. Among these, type 2/4, 3/4, and 4/4 are recommended to be managed with a staged protocol: bone augmentation first, followed by dental implant placement. The selection of barrier membranes for GBR depends on the size of the bone defect, and severe three-dimensional bone deficiencies require additional mechanical support. The digitally fabricated PEEK biological barrier is a product of the world's first digital PEEK bone augmentation system newly developed by Kangtuo Medical Group in 2026. It enables predictable bone gain and contour reconstruction, adapts to irregularly shaped bone defects, and provides complete cell exclusion as well as full soft-tissue isolation without the need for an overlying membrane. The system supports full-workflow planning and clinician-driven design. Being radiolucent, it facilitates sequential observation of bone remodeling, and the device is also easy to retrieve. Nevertheless, its clinical performance following GBR in severe bone defect sites remains to be further evaluated.
  2. Research objective: To evaluate the bone stability and soft tissue healing outcomes following guided bone regeneration (GBR) using a digital PEEK biological barrier in sites with severe bone defects. This study aims to provide evidence based references for clinicians when selecting barrier membranes, so as to facilitate optimal clinical decision making for bone augmentation.
  3. Study design and methods: Design type: multicentral prospective clinical study. Study duration: 3 years. Start time: From the date of adoption of ethics. End time: November 2029. All patients who meet the inclusion criteria at seven study centers will be recruited starting from the date of ethical approval. Each center plans to enroll 2-6 participants. Patients with severe bone defects are screened via pre-implant radiographic examinations for eligibility. All subjects provide written informed consent prior to enrollment in the clinical study. Baseline information including sex, age, and missing tooth position is recorded for all participants. Routine pre-implant assessments are performed at baseline (T0), consisting of radiographic examinations (panoramic radiograph and CBCT), intraoral examination, and pre-surgical intraoral scanning. Based on the intraoral scan and CBCT datasets, the designer reconstructs the original model and simulates the crown contour after bone graft placement, then designs and fabricates the customized PEEK biological barrier. All surgical procedures are performed by one experienced clinician at each participating center. Immediately after surgery (T1), CBCT is obtained to evaluate vertical and horizontal bone augmentation. Suture removal and intraoral scanning are conducted at 2 weeks post GBR to document soft tissue contour, together with patient satisfaction assessed using a visual analogue scale (VAS). At 6-8 months after GBR (T2), intraoral scanning and CBCT are performed to verify whether the augmented bone volume is adequate for implant placement. Subsequently, the PEEK biological barrier is removed, and implants with appropriate diameter and length are inserted. The collected data are analyzed to evaluate bone stability and soft tissue healing outcomes following GBR using the digitally fabricated PEEK biological barrier in sites with severe bone defects.

Studietyp

Interventionell

Inskrivning (Beräknad)

26

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Fuming He
  • Telefonnummer: +8613516817697
  • E-post: hfm@zju.edu.cn

Studera Kontakt Backup

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Aged between 18 and 80 years, in good general health or with mild and controllable systemic diseases, and capable of tolerating implant surgery.
  2. Patients with at least one missing tooth, whose bone defect at the edentulous site is classified as type 2/4, 3/4 or 4/4 according to the Terheyden classification.
  3. If bilateral bone augmentation is required, only one side will be randomly selected for inclusion in this study.
  4. The tooth at the surgical site has been extracted for at least 3 months, and the site is surgically naive.
  5. Sufficient soft tissue contour for staged bone augmentation, including a keratinized gingiva width of at least 2 mm.
  6. All patients undergo bone grafting supported by a digitally fabricated PEEK biological barrier followed by implant placement.
  7. Good oral hygiene status.
  8. Patients are able to understand and actively cooperate with the treatment protocol and have signed the informed consent form.

Exclusion Criteria:

  1. Pregnancy.
  2. Smoking more than 10 cigarettes per day.
  3. Subjects with alcohol abuse or chronic substance misuse.
  4. Long-term use of medications that interfere with bone formation.
  5. Presence of physical deformities that may compromise implant surgery.
  6. A history of local radiotherapy.
  7. Patients with immunodeficiency, including those with HIV infection.
  8. Local inflammation, including untreated periodontitis.
  9. Extensive metallic restorations adjacent to the bone augmentation site.
  10. Oral mucosal disorders, such as oral lichen planus.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: PEEK barrier membrane
Enhet: PEEK barrier membrane

Implantation of a PEEK biological barrier during guided bone regeneration in the area of severe bone deficiency

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Bone augmentation
Tidsram: From enrollment to the end of treatment at 6 months

The cone beam computed tomography (CBCT) data from the two time points (on the day of the initial consultation (T0), and six-eight months after the first surgery (T2) ) were obtained and imported into Mimics Medical software. For each patient, the jaw models at T2 were aligned separately with the jaw model at T0 using point and global registration. After registration and cutting of the digital models, , a Boolean subtraction operation was conducted by subtracting the pre-operative bone segment from the bone segment at 6 months postoperatively to obtain a 6-month postoperative bone increment model. The volumes of the 6-month bone increment can be accessed from the properties menu.
From enrollment to the end of treatment at 6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Bone resorption
Tidsram: From enrollment to the end of treatment at 6 months

The cone beam computed tomography (CBCT) data from the three time points (on the day of the initial consultation (T0), immediately after surgery (T1) and six months after the first surgery (T2) ) were obtained and imported into Mimics Medical software. For each patient, the jaw models at T1 and T2 were aligned separately with the jaw model at T0 using point and global registration. After registration and cutting of the digital models, , a Boolean subtraction operation was conducted by subtracting the pre-operative bone segment from the bone segment at 6 months postoperatively to obtain a 6-month postoperative bone increment model. V1 (volumes of the immediate bone increment) and V2 (volumes of the 6-month bone increment) can be accessed from the properties menu. The resorption rate of bone increment, denoted as RV, can be calculated by utilizing the formula (V1 -V2)/V1.
From enrollment to the end of treatment at 6 months
Bone height change
Tidsram: From enrollment to the end of treatment at 6 months

The STL files of the preoperative bone defect region, immediate postoperative augmented bone, and bone at 6 months postoperatively were imported into the E-3D implant design software with a unified coordinate system. These files were then registered to the CBCT datasets, and the implant site was planned. Using the long axis of the virtually designed implant, an inspection plane was created in the buccolingual direction, from which two-dimensional measurements were acquired. The STL models of bone contours at the three time points were visualized in 2D within the E-3D software. The linear distance between T0 and T2 was recorded as the augmented bone height (H1), and the linear distance between T1 and T2 was recorded as the bone height after six months of healing (H2). The difference between H1 and H2 represented the bone height resorption over the six-month healing period.
From enrollment to the end of treatment at 6 months
Patient satisfaction
Tidsram: From enrollment to the end of treatment at 6 months

postoperative satisfaction through VAS assessment
From enrollment to the end of treatment at 6 months
pseudo-periosteum
Tidsram: At the time of implant placement in the second phase surgery

A periodontal probe was used to measure the pseudo-periosteal thickness at the buccal, palatal, and alveolar crest sites around each implant.
At the time of implant placement in the second phase surgery
Soft tissue healing
Tidsram: From enrollment to the end of treatment at 6 months

Soft tissue healing condition recorded by oral scanning and photography in 2 weeks before and 2 weeks after surgery and 6-8 months after surgery.
From enrollment to the end of treatment at 6 months
Bone width change
Tidsram: From enrollment to the end of treatment at 6 months

The STL files of the preoperative bone defect, immediate postoperative augmented bone, and bone at 6 months postoperatively were imported into the E-3D implant design software under a unified coordinate system. These files were then registered to the CBCT datasets, and the implant site was virtually planned. Using the long axis of the designed implant, an inspection plane was generated in the buccolingual direction for two-dimensional measurement acquisition. The STL models of bone contours at the three time points were visualized in 2D within the E-3D software. For horizontal bone defects, a line perpendicular to the long axis of the designed implant was drawn at the level of the implant platform. Three segment lengths were captured to represent the bone width at baseline, immediately after surgery, and at 6 months postoperatively, respectively. Pairwise subtraction of these values yielded the immediate width gain, the width gain at 6 months, and the width resorption.
From enrollment to the end of treatment at 6 months
Biological complication
Tidsram: From enrollment to the end of treatment at 6 months

Logging PEEK barrier exposure, infection, bone Implantation Failure, etc.
From enrollment to the end of treatment at 6 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Fuming He

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

3 november 2026

Primärt slutförande (Beräknad)

30 augusti 2029

Avslutad studie (Beräknad)

30 november 2029

Studieregistreringsdatum

Först inskickad

31 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

31 oktober 2026

Första postat (Faktisk)

5 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

31 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Andra studie-ID-nummer

  • DHZhejiangU-2026(155)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera